Experiencing neutropenia: Quality of life interviews with adult cancer patients

被引：20

作者：

Fortner B.V. ^{[1
,2
]}

Tauer K.W. ^{[1
]}

Okon T. ^{[2
]}

Houts A.C. ^{[1
,2
]}

Schwartzberg L.S. ^{[1
]}

机构：

[1] West Clinic, Memphis, TN 38104

[2] Supportive Oncology Services and Accelerated Community, Oncology Research Network, Memphis, TN 38138

来源：

BMC Nursing | / 4卷 / 1期

关键词：

Neutropenia; Physical Symptom; Absolute Neutrophil Count; Structure Clinical Interview; Physical Complaint;

D O I：

10.1186/1472-6955-4-4

中图分类号：

学科分类号：

摘要：

Background: Neutropenia is a common toxicity in chemotherapy but detailed information about how neutropenia is associated with changes in patients' quality of life is not readily available. This prospective study interviewed patients with grade 4 neutropenia to provide qualitative information on patients' experience of developing and coping with grade 4 neutropenia during a cycle of chemotherapy. Methods: A sample of 34 patients who developed grade 4 neutropenia during the first cycle of chemotherapy completed a total of 100 structured clinical interviews. Interviews were transcribed, and 2 raters inductively developed 5 broad categories comprising 80 specific complaint domains nominated by patients. Thirty-five patient-nominated problems were mentioned in 5% or more of the interviews. Results: Fatigue was the most common physical symptom. Interference in daily routine, negative self-evaluation, negative emotion, and social isolation were other common complaints associated with neutropenia. Conclusion: Neutropenia is associated with a number of negative experiences among cancer patients undergoing chemotherapy, and these negative experiences have an adverse effect on the patient's quality of life. Oncology nurses can play a key role in helping patients manage adverse effects to maintain their quality of life. © 2005 Fortner et al; licensee BioMed Central Ltd.

引用

共 20 条

[1]

Ropka M.E., Guterbock T., Krebs L., Murphy-Ende K., Stetz K., Summers B., Bissonette E., Given B., Mallory G., Year 2000 Oncology Nursing Society Research Priorities Survey, Oncol Nurs Forum, 29, 3, pp. 481-491, (2002)

[2]

Cella D., Chang C.H., Lai J.S., Webster K., Advances in quality of life measurements in oncology patients, Semin Oncol, 29, 3 SUPPL. 8, pp. 60-68, (2002)

[3]

Haas B.K., Clarification and integration of similar quality of life concepts, Image J Nurs Sch, 31, 3, pp. 215-220, (1999)

[4]

Lyman G.H., Kuderer N.M., Filgrastim in patients with neutropenia: Potential effects on quality of life, Drugs, 62, 1 SUPPL., pp. 65-78, (2002)

[5]

Common Terminology Criteria for Adverse Events V3.0 (CTCAE), (2003)

[6]

Alexander S.W., Pizzo P.A., Current considerations in the management of fever and neutropenia, Curr Clin Top Infect Dis, 19, pp. 160-180, (1999)

[7]

Lehrnbecher T., Chanock S.J., Controversies in the treatment of neutropenia in cancer patients, Curr Opin Hematol, 5, 1, pp. 26-32, (1998)

[8]

Fortner B.V., Stolshek B.S., Tauer K.W., Okon T.A., Durrence H.H., White J., Houts A.C., Schwartzberg L., Chemotherapy-induced neutropenia (CIN) is associated with lower quality of life (QOL) in patients with cancer, Ann of Oncol, 13, 5 SUPPL., (2002)

[9]

Van Deusen-Morrison J., Pupkes J.B., Evidence-based practice guidelines for pro-active management of neutropenia, Oncology Supportive Care Quarterly, 2, 4, pp. 15-19, (2004)

[10]

Lenhart C., Performance improvement to ensure chemotherapy dose delivery, Oncology Supportive Care Quarterly, 2, 4, pp. 6-14, (2004)

← 1 2 →